Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 612 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Anemia, Iron-deficiency
Interventions: Ferric Maltol, Ferrous sulfate; Drug
Lead sponsor: Shield Therapeutics; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 14
States / cities: Saraland, Alabama • Homestead, Florida • Kissimmee, Florida + 10 more

Conditions: Iron Deficiency Anemia
Interventions: Ferric Carboxymaltose (FCM), Iron Sucrose / Iron Dextran; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Non-anemic Iron Deficiency
Interventions: Blood Builder®/Iron Response®; Dietary Supplement
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Head and Neck Cancer
Interventions: Magnetic Resonance Imaging (MRI), Ferumoxytol; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: CKD, Chronic Kidney Diseases, Hepcidin, Ergocalciferol, Vitamin D, Iron-deficiency, Anemia
Interventions: Ergocalciferol 50000 UNT, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Tuberculosis, Iron Deficiency Anemia
Interventions: CHICA Diagnosis Module, CHICA Placebo; Other
Lead sponsor: Indiana University; Other
Eligibility: 3 Years to 11 Years
Enrollment: 2,239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Apical Periodontitis, Pulp Disease, Dental
Interventions: Iron oxide nanoparticles treatment Ferumoxytol/H2O2, NaOCl, NaCl, supplementary irrigation; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Iron Deficiency
Interventions: BioFe; Dietary Supplement
Lead sponsor: Sidero Bioscience, LLC; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Chronic Kidney Failure
Interventions: Fermagate; Drug
Lead sponsor: Ineos Healthcare Limited; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: Pine Bluff, Arkansas • Stuttgart, Arkansas • Charlotte, North Carolina

Conditions: Thalassemia
Interventions: Zinc Supplementation; Dietary Supplement
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 12 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Oakland, California

Conditions: Anemia, Hemolytic
Interventions: Hyperfine Portable MRI; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Iron Overload, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer
Interventions: deferasirox; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Glioblastoma
Interventions: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadoteridol, Magnetic Resonance Imaging; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Columbus, Ohio • Portland, Oregon

Conditions: Rheumatoid Arthritis
Interventions: Indocyanine Green, MultiSpectral Imaging System; Drug · Device
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 89 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Acute Ischemic Stroke AIS, Cerebral Arterial Disease
Interventions: Pulse NanoMED System; Device
Lead sponsor: Euphrates Vascular, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Anemia
Interventions: Ferric Carboxymaltose, Standard Medical Care (SMC); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: Female only
Enrollment: 2,018 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Iron, Blood Level Abnormal
Interventions: Blood Transfusion, Packed red blood cells; Procedure · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Anaemia
Interventions: Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe), Ferrous sulfate containing the stable iron isotope (58Fe); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas

Conditions: Healthy, Iron Overload, Liver Fat
Interventions: Non-contrast MRI with novel MRI software; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 7 Years and older
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Iron-deficiency, Iron Deficiency Anemia, Iron Deficiency Anemia Treatment
Interventions: Iron supplement with a lunch meal containing beef, Iron supplement with a lunch meal containing plant-based alternative; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hot Flashes, Menopause, Vasomotor System; Labile
Interventions: Sympathoexcitatory stressors, Sodium Nitroprusside, Acetylcholine, Terbutaline, Norepinephrine; Other · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Femoral Fracture, Fragility Fracture, Muscle Atrophy
Interventions: Essential Amino Acid Supplementation; Combination Product
Lead sponsor: Michael C Willey; Other
Eligibility: 65 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Iowa City, Iowa • Eugene, Oregon

Conditions: Iron Deficiency Anemia Treatment, Iron-deficiency, Iron Deficiency Anemia Due to Blood Loss, Iron Deficiency Anemia
Interventions: Packed red blood cells, Intravenous drug; Biological · Drug
Lead sponsor: Texas Tech University Health Sciences Center, El Paso; Other
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Chronic Inflammation, Inflammaging
Interventions: Dietary supplement, Placebo; Dietary Supplement · Other
Lead sponsor: Edifice Health; Industry
Eligibility: 18 Years and older
Enrollment: 781 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Greenbrae, California • Suwanee, Georgia

Search by objective public record fields.

Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years

Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women

Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women

Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI

Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease

Universal Screening for Tuberculosis and Anemia With the CHICA System

A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment

Safety and Tolerability of BioFe for Iron Deficiency Management

An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate

Zinc and Diabetes in Patients With Thalassemia: a Pilot Study

Ferumoxytol Enhanced Hyperfine Low Field Strength MRI

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma

Near InfraRed Fluorescence Using Indocyanine Green and Magnetic Resonance Lymphography of Lymphatic Transport

Pulse Endovascular ReperFUSION for Acute Ischemic Stroke

Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients

Duration of Red Blood Cell Storage Prior to Transfusion

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

Fully Automated High-Throughput Quantitative MRI of the Liver

Meals to Improve Absorption of Iron Supplements

Hot Flashes and Neurovascular Function in Women

Essential Amino Acid Supplementation for Femoral Fragility Fractures

IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department

2021 PMT iAge® Intervention Trial by Edifice Health